Begoña Graña

1.7k total citations
37 papers, 609 citations indexed

About

Begoña Graña is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Begoña Graña has authored 37 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 10 papers in Genetics and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Begoña Graña's work include Colorectal Cancer Treatments and Studies (15 papers), BRCA gene mutations in cancer (10 papers) and Genetic factors in colorectal cancer (7 papers). Begoña Graña is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), BRCA gene mutations in cancer (10 papers) and Genetic factors in colorectal cancer (7 papers). Begoña Graña collaborates with scholars based in Spain, United States and Palestinian Territory. Begoña Graña's co-authors include Judith Balmañà, Joan Brunet, José Baselga, Judy E. Garber, Eric P. Winer, Cristina Saura, Steven J. Isakoff, Nadine Tung, Elizabeth Lowe and Paul Frewer and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Begoña Graña

34 papers receiving 601 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Begoña Graña Spain 11 331 270 200 104 102 37 609
Paul Gesta France 10 213 0.6× 127 0.5× 112 0.6× 58 0.6× 53 0.5× 17 421
Amnon Amit Israel 10 408 1.2× 131 0.5× 237 1.2× 48 0.5× 55 0.5× 31 739
Sarah A. Bannon United States 14 285 0.9× 180 0.7× 166 0.8× 303 2.9× 155 1.5× 33 743
JudyE. Garber United States 5 327 1.0× 329 1.2× 282 1.4× 353 3.4× 252 2.5× 5 787
Ashley D. Staton United States 9 171 0.5× 124 0.5× 69 0.3× 107 1.0× 55 0.5× 20 340
Paul Bessette Canada 18 237 0.7× 111 0.4× 208 1.0× 56 0.5× 65 0.6× 44 730
M J Worsham United States 12 203 0.6× 210 0.8× 262 1.3× 63 0.6× 182 1.8× 18 566
D. Mirchandani United States 7 165 0.5× 78 0.3× 101 0.5× 29 0.3× 88 0.9× 15 379
Rachel McFarland United States 9 248 0.7× 673 2.5× 335 1.7× 326 3.1× 373 3.7× 14 936
Alessandro Bovicelli Italy 18 221 0.7× 68 0.3× 165 0.8× 42 0.4× 79 0.8× 38 749

Countries citing papers authored by Begoña Graña

Since Specialization
Citations

This map shows the geographic impact of Begoña Graña's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Begoña Graña with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Begoña Graña more than expected).

Fields of papers citing papers by Begoña Graña

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Begoña Graña. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Begoña Graña. The network helps show where Begoña Graña may publish in the future.

Co-authorship network of co-authors of Begoña Graña

This figure shows the co-authorship network connecting the top 25 collaborators of Begoña Graña. A scholar is included among the top collaborators of Begoña Graña based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Begoña Graña. Begoña Graña is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cajal, Teresa Ramón y, Marta Pineda, Elena Aguirre, et al.. (2023). SEOM clinical guideline on heritable TP53-related cancer syndrome (2022). Clinical & Translational Oncology. 25(9). 2627–2633. 4 indexed citations
3.
Casta, Adelaida La, Teresa Macarulla, Míriam Juárez, et al.. (2023). 126P Biliary tract cancer (BTC) characterization on a cohort of patients (pt) from the Spanish RETUD Registry. Annals of Oncology. 34. S230–S230. 1 indexed citations
4.
Alonso, Vicente, Ismael Macías, Javier Gállego, et al.. (2023). 595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703). Annals of Oncology. 34. S430–S431. 2 indexed citations
5.
Bonilla, Carlos, Juan Manuel O’Connor, O. Hernando, et al.. (2023). Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer. Cancers. 15(17). 4373–4373. 2 indexed citations
6.
Lago, Nieves Martínez, Ana Fernández Montés, Jose Carlos Méndez, et al.. (2021). Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain. BMC Cancer. 21(1). 64–64. 8 indexed citations
7.
Capdevila, Jaume, Ismael Macías, Joan Maurel, et al.. (2020). Phase II study of durvalumab plus total neoadjuvant therapy (TNT) in locally advanced rectal cancer: The GEMCAD-1703 DUREC trial.. Journal of Clinical Oncology. 38(15_suppl). TPS4122–TPS4122. 5 indexed citations
8.
9.
10.
Llort, Gemma, Isabel Chirivella, Rafael Morales, et al.. (2015). SEOM clinical guidelines in Hereditary Breast and ovarian cancer. Clinical & Translational Oncology. 17(12). 956–961. 81 indexed citations
11.
Balmañà, Judith, Nadine Tung, Steven J. Isakoff, et al.. (2014). Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Annals of Oncology. 25(8). 1656–1663. 126 indexed citations
12.
Gadea, Neus, Joan Brunet, Teresa Ramón y Cajal, et al.. (2012). What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure?. The Breast. 21(6). 755–760. 32 indexed citations
13.
Tabernero, Josep, Cristina Saura, Susana Roselló, et al.. (2011). First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068.. Journal of Clinical Oncology. 29(15_suppl). 3022–3022. 10 indexed citations
14.
Graña, Begoña, Laura Fachal, Esther Darder, et al.. (2011). Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry. Breast Cancer Research and Treatment. 128(2). 573–579. 7 indexed citations
15.
Castellvı́-Bel, Sergi, Ceres Fernández–Rozadilla, Francesc Balaguer, et al.. (2009). Molecular analysis of the APC and MUTYH genes in Galician and Catalonian FAP families: a different spectrum of mutations?. BMC Medical Genetics. 10(1). 57–57. 37 indexed citations
16.
Monteagudo, Benigno, et al.. (2009). Metástasis cutánea inflamatoria zosteriforme por carcinoma de mama. Piel. 24(6). 343–343. 1 indexed citations
17.
Balmañà, Judith, Begoña Graña, Esther Darder, et al.. (2008). Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort. Human Reproduction. 24(4). 1000–1006. 59 indexed citations
18.
Graña, Begoña, Ana Vega, & Juan Cueva. (2005). Cáncer de mama y ovario hereditario:consejo genético, seguimiento y reducción del riesgo. Complutensian Scientific Journals (Complutense University of Madrid). 2(2). 229–242. 1 indexed citations
19.
Barón-López, Francisco Javier, Begoña Graña, Teresa Curiel, et al.. (2001). Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer. European Journal of Cancer. 37(11). 1381–1384. 8 indexed citations
20.
Sanz‐Ortega, Julián, et al.. (1996). Hepatocellular Carcinomas Diagnosed Following Metastasis to the Oral Cavity. Report of 2 Cases. Journal of Periodontology. 67(7). 717–719. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Gesta Breakdown of academic impact, for papers by Amnon Amit Breakdown of academic impact, for papers by Sarah A. Bannon Breakdown of academic impact, for papers by JudyE. Garber Breakdown of academic impact, for papers by Ashley D. Staton Breakdown of academic impact, for papers by Paul Bessette Breakdown of academic impact, for papers by M J Worsham Breakdown of academic impact, for papers by D. Mirchandani Breakdown of academic impact, for papers by Rachel McFarland Breakdown of academic impact, for papers by Alessandro Bovicelli
Rankless by CCL
2026